BTIG raised the firm’s price target on Exact Sciences (EXAS) to $75 from $65 and keeps a Buy rating on the shares. The firm notes shares of Exact Sciences are up following news that the company obtained a price of about $592/test for Cologuard Plus, or a 16% price increase compared to its first generation Cologuard test. BTIG says that while the firm and most investors expected some price increase for Cologuard Plus, the actual amount and mechanism of the increase was uncertain, with today’s news helping to derisk the stock.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $86 from $82 at TD Cowen
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS
- Exact Sciences to present abstracts on multi-cancer early detection test
- Exact Sciences price target lowered to $75 from $85 at Piper Sandler